Upsher-Smith Laboratories, Inc. - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Upsher-Smith Laboratories, Inc. - Product Pipeline Review - 2014" provides data on the Upsher-Smith Laboratories, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Upsher-Smith Laboratories, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Upsher-Smith Laboratories, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Upsher-Smith Laboratories, Inc. - Brief Upsher-Smith Laboratories, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Upsher-Smith Laboratories, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Upsher-Smith Laboratories, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Upsher-Smith Laboratories, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Upsher-Smith Laboratories, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Upsher-Smith Laboratories, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Upsher-Smith Laboratories, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Upsher-Smith Laboratories, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Upsher-Smith Laboratories, Inc. and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Upsher-Smith Laboratories, Inc. Snapshot 6
Upsher-Smith Laboratories, Inc. Overview 6
Key Information 6
Key Facts 6
Upsher-Smith Laboratories, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Upsher-Smith Laboratories, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Upsher-Smith Laboratories, Inc. - Pipeline Products Glance 12
Upsher-Smith Laboratories, Inc. - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
Upsher-Smith Laboratories, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Upsher-Smith Laboratories, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Upsher-Smith Laboratories, Inc. - Drug Profiles 18
topiramate ER 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
midazolam hydrochloride 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
naluzotan 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
PRX-00933 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
PRX-167700 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
tonabersat 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Alpha-7 Program 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CCR2 Antagonist 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CXCR4 Antagonist 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
D1 PAM 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PAR-2 Program 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PRX-1 Program 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PRX-1354 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SSAO Inhibitor 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
TrkA Program 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Protein Kinase Inhibitors 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Upsher-Smith Laboratories, Inc. - Pipeline Analysis 34
Upsher-Smith Laboratories, Inc. - Pipeline Products by Therapeutic Class 34
Upsher-Smith Laboratories, Inc. - Pipeline Products by Target 36
Upsher-Smith Laboratories, Inc. - Pipeline Products by Route of Administration 38
Upsher-Smith Laboratories, Inc. - Pipeline Products by Molecule Type 39
Upsher-Smith Laboratories, Inc. - Pipeline Products by Mechanism of Action 40
Upsher-Smith Laboratories, Inc. - Recent Pipeline Updates 42
Upsher-Smith Laboratories, Inc. - Dormant Projects 52
Upsher-Smith Laboratories, Inc. - Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
Upsher-Smith Laboratories, Inc., Key Information 6
Upsher-Smith Laboratories, Inc., Key Facts 6
Upsher-Smith Laboratories, Inc. - Pipeline by Indication, 2014 9
Upsher-Smith Laboratories, Inc. - Pipeline by Stage of Development, 2014 10
Upsher-Smith Laboratories, Inc. - Monotherapy Products in Pipeline, 2014 11
Upsher-Smith Laboratories, Inc. - Pre-Registration, 2014 12
Upsher-Smith Laboratories, Inc. - Phase III, 2014 13
Upsher-Smith Laboratories, Inc. - Phase II, 2014 14
Upsher-Smith Laboratories, Inc. - Phase I, 2014 15
Upsher-Smith Laboratories, Inc. - Preclinical, 2014 16
Upsher-Smith Laboratories, Inc. - Discovery, 2014 17
Upsher-Smith Laboratories, Inc. - Pipeline by Therapeutic Class, 2014 35
Upsher-Smith Laboratories, Inc. - Pipeline by Target, 2014 37
Upsher-Smith Laboratories, Inc. - Pipeline by Route of Administration, 2014 38
Upsher-Smith Laboratories, Inc. - Pipeline by Molecule Type, 2014 39
Upsher-Smith Laboratories, Inc. - Pipeline Products by Mechanism of Action, 2014 41
Upsher-Smith Laboratories, Inc. - Recent Pipeline Updates, 2014 42
Upsher-Smith Laboratories, Inc. - Dormant Developmental Projects,2014 52
Upsher-Smith Laboratories, Inc., Other Locations 53
Upsher-Smith Laboratories, Inc., Subsidiaries 54